Autologous versus allogeneic cell-based vaccines?

Cancer Journal

Volumn 17, Issue 5, 2011, Pages 331-336

  Parmiani, Giorgio ^a   Pilla, Lorenzo ^a   MacCalli, Cristina ^a   Russo, Vincenzo ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

clinical response; gene modified cancer cells; immune response; metastatic disease; Tumor cell vaccines

Indexed keywords

CANCER VACCINE; CANVAXIN; GENE PRODUCT; IMMUNOLOGICAL ADJUVANT; TUMOR CELL VACCINE;

ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; BCG VACCINATION; CANCER IMMUNIZATION; CANCER PATIENT; CANCER PREVENTION; CELL THERAPY; CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; GENE INSERTION; GENE VECTOR; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CELL TRANSPLANTATION; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MICE; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 80053367757     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e3182337a76     Document Type: Review

References (70)

1. Morton DL, Hsueh EC, Essner R, et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg. 2002;236:438-449.
2. Jocham D, Richter A, Hoffmann L, et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet. 2004;363:594-599. (Pubitemid 38264176)
3. Vermorken JB, Claessen AM, van Tinteren H, et al. Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial. Lancet. 1999;353:345-350. (Pubitemid 29088160)
4. Harris JE, Ryan L, Hoover HC Jr, et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J Clin Oncol. 2000;18:148-157. (Pubitemid 30036348)
5. Anichini A, Maccalli C, Mortarini R, et al. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993;177:989-998. (Pubitemid 23097388)
6. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647. (Pubitemid 21917508)
7. Kawakami T, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91:3515-3519. (Pubitemid 24139460)
8. Tosolini M, Kirilovsky A, Mlecnik B, et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (TH1, TH2, Treg, TH17) in patients with colorectal cancer. Cancer Res. 2011;71:1263-1271.
9. Parmiani G, Castelli C, Dalerba P, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst. 2002;94:805-818. (Pubitemid 34705052)
10. Boon T, Coulie PG, Van den Eynde B, et al. Human T cell responses against melanoma. Ann Rev Immunol. 2006;24:75-208.
11. Gansbacher B, Zier K, Daniels B, et al. Interleukin-2 gene transfer into tumor cells abrogate tumorigenicity and induces protective immunity. J Exp Med. 1990;172:1217-1224. (Pubitemid 20343223)
12. Golumbek PT, Lazenby AJ, Levitsky HI, et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991;254:713-716. (Pubitemid 21917394)
13. Colombo MP, Modesti A, Parmiani G, et al. Local cytokine availability elicits tumor rejection and systemic immunity through granulocyteY T-lymphocyte cross talk. Cancer Res. 1992;52:4853-4857.
14. Allione A, Consalvo M, Nanni P, et al. Immunizing and curative potential of replicating and non-replicating murine mammary adenocarcinoma cells engineered with interleukin (IL)-2, IL-4, IL-6, IL-7, IL-10, tumor necrosis factor-, granulocyte-macrophage colony-stimulating factor, and F-interferon gene or admixed with conventional adjuvants. Cancer Res. 1994;54:6022-6026.
15. Kircheis R, Kupku Z, Wallner G, et al. Interleukin-2 gene-modified allogeneic melanoma cell vaccines can induce cross-protection against syngeneic tumors in mice. Cancer Gene Ther. 2000;7:870-878. (Pubitemid 30437287)
16. Colombo MP, Ferrari G, Stoppacciaro A, et al. Granulocyte colonystimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med. 1991;173:889-897.
17. Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colonystimulating factor stimulates potent, specific and long lasting anti-tumor immunity. Proc Natl Acad Sci U S A. 1993;90:3539-3543. (Pubitemid 23111402)
18. Colombo MP, Rodolfo M. Tumor cells engineered to produce cytokines or cofactors as cellular vaccines: do animal studies really support clinical trials? Cancer Immunol Immunother. 1995;4:265-270. (Pubitemid 26007606)
19. Uchiyama A, Hoon DSB, Morisaki T, et al. Transfection of interleukin-2 gene into human melanoma cells augments cellular immune response. Cancer Res. 1993;53:949-952. (Pubitemid 23087889)
20. Arienti F, Sulè-Suso J, Melani C, et al. IL-2 gene-transduced human melanoma cells efficiently stimulate MHC-unrestricted and MHCrestricted autologous lymphocytes. Hum Gene Ther. 1994;5:1139-1150.
21. Miller AR, McBrids WH, Dubinett SM, et al. Transduction of human melanoma cell lines with the human interleukin-7 gene using retroviralmediated gene transfer: comparison of immunologic properties with interleukin-2. Blood. 1993;82:3686-3694. (Pubitemid 24006051)
22. Ogasawara M, Rosenberg SA. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with F-interferon genes. Cancer Res. 1993;53:3561-3568. (Pubitemid 23229637)
23. Mazzocchi A, Melani C, Rivoltini L, et al. Simultaneous transduction of B7.1 and IL-2 genes into human melanoma cells to be used as vaccine: enhancement of stimulatory activity for autologous and allogeneic lymphocytes. Cancer Immunol Immunother. 2001;50:199-211. (Pubitemid 32662402)
24. Abdel-Wahab Z, Weltz C, Hester D, et al. A phase I clinical trial of immunotherapy with interferon-F gene-modified autologous melanoma cells. Cancer. 1997;80:401-412.
25. Moller P, Sun Y, Dorbic T, et al. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status. Br J Cancer. 1998;77:1907-1916.
26. Soiffer R, Lynch T, Mihm M, et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 1998;95: 13141-13146.
27. Nemunaitis J, Bohart C, Fong T, et al. Phase I trial of retroviral vectormediated interferon (IFN)-F gene transfer into autologous tumor cells in patients with metastatic melanoma. Cancer Gene Ther. 1998;5:292-300. (Pubitemid 128640015)
28. Schreiber S, Kampgen E, Wagner E, et al. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin- 2-transfected cancer cells: outcome of a phase I study. Human Gene Ther. 1999;10:983-993. (Pubitemid 29195428)
29. Palmer K, Moore J, Everard M, et al. Gene therapy with autologous, interleukin-2-secreting tumor cells in patients with malignant melanoma. Human Gene Ther. 1999;10:1261-1268. (Pubitemid 29267581)
30. Soiffer R, Hodi FS, Haluska F, et al. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. J Clin Oncol. 2003;21:3343-3350. (Pubitemid 46606268)
31. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941-1949. (Pubitemid 28446683)
32. Nemunaitis J, Sterman D, Jablons D, et al. Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer. J Natl Cancer Inst. 2004;96:326-331. (Pubitemid 38256277)
33. Fishman M, Hunter TB, Soliman H, et al. Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma. J Immunother. 2008;1:72-80. (Pubitemid 351619406)
34. Wittig B, Marten A, Dorbic S, et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Human Gene Ther. 2001;12:267-278. (Pubitemid 32163898)
35. Dols A, Meijer SL, Hu H-M, et al. Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother. 2003;26:163-170. (Pubitemid 36292787)
36. Berd D. M-Vax: an autologous, hapten-modified vaccine for human cancer. Exp Opin Biol Ther. 2002;2:335-342. (Pubitemid 34464814)
37. Sensi M, Farina C, Maccalli C, et al. Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. J Clin Invest. 1997;99:710-717. (Pubitemid 27097673)
38. Sulè-Suso J, Arienti F, Melani C, et al. A B7-1 transfected human melanoma line stimulate proliferation and cytotoxicity of autologous and allogeneic lymphocytes. Eur J Immunol. 1995;25:2737-2742.
39. Yang S, Darrow TL, Seigler HF. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class -matched allogeneic peripheral blood lymphocytes by B7 geneY modified melanoma cells. Cancer Res. 1997;57:1561-1568. (Pubitemid 27175575)
40. Antonia SJ, Seigne J, Diaz J, et al. Phase I trial, of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J Urol. 2002;167:1995-2000. (Pubitemid 34309645)
41. Nemunaitis J, Fong T, Burrows F, et al. Phase I trial of interferon-F retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma. Human Gene Ther. 1999;10:1289-1298. (Pubitemid 29267584)
42. Steward AK, Lassam NJ, Quirt IC, et al. Adenovector-mediated gene delivery of interleukin-2 in metastatic breast cancer and melanoma: results of a phase 1 clinical trial. Gene Ther. 1999;6:35-63.
43. Stopeck AT, Jones A, Hersh EM, et al. Phase II study of direct intralesional gene transfer of allovectin-7, an HLA-B7/A2-microglobulin DNA-liposome complex, in patients with metastatic melanoma. Clin Cancer Res. 2001;7:2285-2291. (Pubitemid 32751626)
44. Rochlitz C, Dreno B, Jantscheff P, et al. Immunotherapy of metastatic melanoma by intratumoral injections of Vero cells producing human IL-2: phase II randomized study comparing two dose levels. Cancer Gene Ther. 2002;9:289-295. (Pubitemid 34205504)
45. Triozzi PL, Allen KO, Carlisle RR, et al. Phase I study of the intratumoral administration of recombinant canarypox viruses ex pressing B7.1 and interleukin 12 in patients with metastatic melanoma. Clin Cancer Res. 2005;11-41:68-75.
46. Bedikian AY, Richards J, Kharkevitch D, et al. A phase 2 study of high dose allovectin-7 in patients with an advanced metastatic melanoma. Melanoma Res. 2010;20:218-226.
47. Mastrangelo MJ, Maguire H Jr, Eisenlohr LC, et al. Intratumoral recombinant GM-CSF-encoding virus as gene therapy in patients with cutaneous melanoma. Cancer Gene Ther. 1999;6:409-422. (Pubitemid 129667814)
48. Avigan D, Vasir B, Gong J, et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin Cancer Res. 2004;10:4699-4708. (Pubitemid 38955520)
49. Ehelken H, Schadendorf D, Eichmuller S. Humoral immune response against melanoma antigens induced by vaccination with cytokine genemodified autologous tumor cells. Int J Cancer. 2004;108:307-313. (Pubitemid 37541788)
50. Maio M, Fonsatti E, Lamaj E, et al. Vaccination of stage IV patients with allogeneic IL-4 or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol Immunother. 2002;51:9-14. (Pubitemid 34158518)
51. Arienti F, Sulè-Suso J, Belli F, et al. Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. Human Gene Ther. 1996;7:1955-1963.
52. Bowman LC, Grossmann M, Rill D, et al. Interleukin-2 gene-modified allogeneic tumor cells for treatment of relapsed neuroblastoma. Human Gene Ther. 1998;9:1303-1311. (Pubitemid 28312895)
53. Arienti F, Belli F, Napolitano F, et al. Vaccination of melanoma patients with interleukin 4 gene-transduced allogeneic melanoma cells. Human Gene Ther. 1999;10:2907-2916.
54. Osanto S, Schiphorst PP, Weijl NI, et al. Vaccination of melanoma patients with an allogeneic, genetically modified interleukin-2 producing melanoma cell line. Human Gene Ther. 2000;11:739-750. (Pubitemid 30180278)
55. Nawrocki S, Murawa P, Malicki J, et al. Genetically modified tumour vaccines (GMTV) in melanoma clinical trial. Immunol Letters. 2000; 74:81-86.
56. Small EJ, Sacks N, Nemunaitis J, et al. Granulocyte macrophage colonystimulating factor-secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007;13:3883-3891. (Pubitemid 47037595)
57. Brill TH, Kubler HR, von Randenburgh H, et al. Allogeneic retrovirally transduced, IL-2 and IFN-F-secreting cancer cell vaccine in patients with hormone refractory prostate cancer-a phase I clinical trial. J Gene Med. 2007;9:547-560. (Pubitemid 47073987)
58. Laheru D, Lutz E, Burke J, et al. Allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clin Cancer Res. 2008;14:1455-1463. (Pubitemid 351413929)
59. Buchner A, Pohla H, Willinski G, et al. Phase I trial of allogeneic genemodified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma. Human Gene Ther. 2010;21:285-297.
60. Le DT, Pardoll DM, Jaffee EM. Cellular vaccine approach. Cancer J. 2010:16:304-310.
61. Faries MB, Hsueh EC, Ye X, et al. Effect of granulocyte/macrophage colony-stimulating factor on vaccination with an allogeneic whole-cell melanoma vaccine. Clin Cancer Res. 2009;15:7029-7035.
62. Filipazzi P, Valenti R, Huber V, et al. Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol. 2007;25:2546-2553. (Pubitemid 47041228)
63. Sondak VK, Sabel MS, Mulé JJ. Allogeneic and autologous melanoma vaccines: where havewe been and where arewe going? Clin Cancer Res. 2006;12:2337s-2341s.
64. Garrido F, Algarra I, Garcìa-Lora AM. The escape of cancer from T lymphocytes: immunoselection of MHC class I loss variants harbouring structural-irreversible "hard" lesions. Cancer Immunol Immunother. 2010;59:1601-1606.
65. Heath WR, Belz GT, Behrens GM, et al. Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens. Immunol Rev. 2004;199:9-26. (Pubitemid 38736761)
66. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007; 25:267-296. (Pubitemid 46697910)
67. De Monte L, Reni M, Tassi E, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208:469-478.
68. Malek TR, Castro I. Interleukin-2 receptor signaling: at the interface between tolerance and immunity. Immunity. 2010;33:153-165.
69. Schwartzentruber DJ, Lawson DH, Richards JM, et al. gp100 Peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364:2119-2127.
70. Rosenberg SA, Yang JC, Sherry RM, et al. Durable complete responses in Heavily pretreated patients with metastatic melanoma using T cell transfer immunotherapy [published online ahead of print May 11, 2011]. Clin Cancer Res. 17:4550-4557.